tiprankstipranks
Trending News
More News >
TipRanksTop Financial ExpertsInsidersFairmount Funds Management LLC

Fairmount Funds Management LLC Insider Profile

25 Followers
Fairmount Funds Management LLC, Director at Cogent Biosciences, holds 2.21M shares in Zenas BioPharma, Inc. (Ticker: ZBIO), holds 4.55M shares in Jade Biosciences (Ticker: JBIO), holds 3.71M shares in Oruka Therapeutics (Ticker: ORKA). Most recently, Fairmount Funds Management LLC Bought ― shares of Zenas BioPharma, Inc. on Oct 09, 2025 for an estimated value of $6.01M.
tipranks
Fairmount Funds Management LLC

Fairmount Funds Management LLC
Cogent Biosciences (COGT)
Director

Ranked #2,147 out of 103,913 Corporate Insiders

Profitable Transactions

64%
9 out of 14 Profitable Transactions

Average Return

+46.00%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark

Insider Holdings

$752M
19.62%
15.77%
14.43%
13.54%
36.64% Others
A breakdown of Fairmount Funds Management LLC's holdings

Insider Roles

Cogent Biosciences
(COGT)
Director
Apogee Therapeutics
(APGE)
Director
Spyre Therapeutics
(SYRE)
Director
Oruka Therapeutics
(ORKA)
Director, Ten Percent Owner
+5 other positions
Roles that Fairmount Funds Management LLC holds in companies

Most Profitable Insider Trade

Stock:
Apogee Therapeutics
(APGE)
Rating:Informative Buy
Date:Jul 17, 2023 - Jul 17, 2024
Return:+136.50%
The most profitable trade made by Fairmount Funds Management LLC

Fairmount Funds Management LLC's Trading History

Company Name
Last Transaction Date
Insider Position
Last Transaction
Last Transaction Amount
Holding Value
Cogent Biosciences
Jul 14, 2025
Director
Informative Buy
25.00M
$147.57M
Viridian Therapeutics
Jun 11, 2025
Director, Ten Percent Owner
Uninformative Buy
166.35K
$83.76M
Apogee Therapeutics
Apr 01, 2024
Director
Uninformative Buy
$118.63M
Dianthus Therapeutics
Oct 01, 2024
Director
Uninformative Sell
$96.28M
Spyre Therapeutics
Apr 25, 2024
Director
Uninformative Buy
118.18M
$108.53M
Oruka Therapeutics
Sep 19, 2025
Director, Ten Percent Owner
Uninformative Buy
5.00M
$101.82M
Zenas BioPharma, Inc.
Oct 09, 2025
Director
Informative Buy
6.01M
$52.91M
Jade Biosciences
Oct 08, 2025
Director, Ten Percent Owner
Uninformative Buy
12.18M
$42.67M
Crescent Biopharma
Director, Ten Percent Owner
List of latest transactions for each holding click on a transaction to see Fairmount Funds Management LLC's performance on stock

Fairmount Funds Management LLC insider profile FAQ

What is the percentage of profitable transactions made by Fairmount Funds Management LLC?
The percentage of profitable transactions made by Fairmount Funds Management LLC is 64%.
    What is the average return per transaction made by Fairmount Funds Management LLC?
    The average return per transaction made by Fairmount Funds Management LLC is 46.00%.
      What stocks does Fairmount Funds Management LLC hold?
      Fairmount Funds Management LLC holds: COGT, VRDN, APGE, DNTH, SYRE, ORKA, ZBIO, JBIO, CBIO stocks.
        What was Fairmount Funds Management LLC’s latest transaction?
        Fairmount Funds Management LLC latest transaction was an Informative Buy of $6.01M.
          What was Fairmount Funds Management LLC's most profitable transaction?
          Fairmount Funds Management LLC’s most profitable transaction was an Informative Buy of APGE stock on July 17, 2023. The return on the trade was 136.50%.
            What is Fairmount Funds Management LLC's role in Cogent Biosciences?
            Fairmount Funds Management LLC's role in Cogent Biosciences is Director.
              How can I follow the stock ratings of top corporate insiders?
              Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.